MUSES研究:1360例接受内镜手术为基础治疗的鼻窦癌患者预后研究——多机构内镜治疗鼻窦癌协作研究
该多机构预后研究纳入1995至2021年5家转诊医院接受经鼻内镜手术(TES)治疗的1360例鼻窦癌患者,训练集940例、验证集420例。训练集5年总生存率和无复发生存率分别为72.7%(95%CI 69.5-76.0%)和66.4%(95%CI 63.1-69.8%),随组织学类型显著变化。列线图内部与外部验证除黏膜黑色素瘤外均满意(乐观校正C-index>0.7,累积AUC>0.7)。
要点
- 训练集5年总生存率72.7%(95%CI 69.5-76.0%),无复发生存率66.4%(95%CI 63.1-69.8%)。
- 预后随组织学类型显著不同,年龄、性别、既往治疗、切除范围、分级/亚型、T分期、淋巴结状态、切缘状态和辅助治疗均与预后相关。
- 列线图验证除黏膜黑色素瘤外均满意(乐观校正C-index>0.7,累积AUC>0.7)。
核心结论
- 以TES为基础治疗鼻窦癌的结局随组织学类型差异显著,该大型非人群研究为适合接受含TES治疗的患者提供了预后基准数据。
研究设计与样本
- 多机构预后研究,纳入1995至2021年5家转诊医院所有接受含TES治疗的患者,训练集来自3个欧洲中心(940例),验证集来自2个非欧洲中心(420例),多变量模型转化为列线图。
主要发现
- 训练集5年总生存率为72.7%(95%CI 69.5-76.0%),5年无复发生存率为66.4%(95%CI 63.1-69.8%),随组织学类型显著变化。
- 训练集与验证集在手术时平均年龄、原发与复发表现、组织学分布、手术类型、T分期和辅助治疗类型上分布不同。
- 多变量分析中,年龄、性别、既往治疗、颅侧/外侧/后外侧轴切除范围、分级/亚型、T分期、淋巴结状态、切缘状态和辅助治疗均与不同预后结局相关,其显著性和效应量因组织学而异。
关键数值与推荐
- 列线图内部和外部验证在所有组织学类型中均满意(乐观校正C-index>0.7,累积AUC>0.7),但黏膜黑色素瘤除外。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over the last 2 decades, transnasal endoscopic surgery (TES) has become the most frequently employed surgical technique to treat sinonasal malignancies. The rarity and heterogeneity of sinonasal cancers have hampered large non-population-based analyses. METHODOLOGY: All patients receiving TES-including treatment between 1995 and 2021 in 5 referral hospitals were included. A prognostic study was performed, and multivariable models were transformed into nomograms. Training and validation sets were based on results from 3 European and 2 non-European centres, respectively. RESULTS: The training and validation set included 940 and 420 patients, respectively. The mean age at surgery, primary-versus-recurrent presentation, histology distribution, type of surgery, T category and type of adjuvant treatment were differently distributed in the training and validation set. In the training set, 5-year overall survival and recurrence-free survival with a 95%-confidence interval were 72.7% (69.5-76.0%) and 66.4% (63.1-69.8%), respectively, significantly varying with histology. At multivariable analyses, age, gender, previous treatment, the extent of resection on the cranial, lateral and posterolateral axes, grade/subtype, T category, nodal status, margin status and adjuvant treatment were all associated with different prognostic outcomes, displaying a heterogeneous significance and effect size according to histology. The internal and external validation of nomograms was satisfactory (optimism-corrected C-index >0.7 and cumulative area under curve >0.7) for all histologies but mucosal melanoma. CONCLUSIONS: Outcomes of TES-based treatment of sinonasal cancers vary substantially with histology. This large, non-population-based study provides benchmark data on the prognosis of sinonasal cancers that are deemed suitable for treatment including TES.
引用
- Ferrari M, Mattavelli D, Tomasoni M, et al. The MUSES∗: a prognostic study on 1360 patients with sinonasal cancer undergoing endoscopic surgery-based treatment: ∗MUlti-institutional collaborative Study on Endoscopically treated Sinonasal cancers. Eur J Cancer. 2022. PMID: 35724468. doi:10.1016/j.ejca.2022.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。